| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| 3750% | ₹796.95 0% | 4,800 | ₹2.9 0% | 5000% |
| - | - | 4,900 | ₹1.3 0% | 3750% |
| 1250% | ₹720 0% | 5,000 | ₹3.8 -24% | 3750% |
| - | - | 5,050 | ₹2.75 -34.52% | 7,37518% |
| - | - | 5,100 | ₹4.5 34.32% | 13,750205.55% |
| - | - | 5,150 | ₹3.95 6.75% | 4,7508.57% |
| - | - | 5,200 | ₹3.95 11.26% | 9,375-21.05% |
| - | - | 5,250 | ₹4 -1.23% | 8,2500% |
| 1250% | ₹472.75 0% | 5,300 | ₹4.3 -11.34% | 11,375-2.15% |
| 6250% | ₹226.2 -0.02% | 5,350 | ₹8.85 -3.8% | 4,0000% |
| - | - | 5,400 | ₹6.55 -10.88% | 11,500-6.12% |
| 1250% | ₹209.3 0% | 5,450 | ₹8.55 -17.78% | 24,5008.28% |
| 1,8750% | ₹115.9 -27.74% | 5,500 | ₹14.35 -9.17% | 31,125-11.70% |
| 3,00014.28% | ₹82.7 -23.91% | 5,550 | ₹27 12.03% | 11,375-19.46% |
| 32,00049.70% | ₹47.15 -41.17% | 5,600 | ₹48 25.65% | 10,875-17.14% |
| 16,8756.29% | ₹27.5 -43.24% | 5,650 | ₹76 29.58% | 9,375-23.46% |
| 41,25010% | ₹15.8 -50.31% | 5,700 | ₹115.65 23.55% | 9,375-12.79% |
| 10,625-31.45% | ₹9.7 -50.51% | 5,750 | ₹222.9 0% | 8,7500% |
| 55,3751.37% | ₹6 -53.48% | 5,800 | ₹282.45 0% | 14,8750% |
| 8,75034.61% | ₹4.75 18.75% | 5,850 | ₹257.1 21.5% | 1,50033.33% |
| 26,375-4.09% | ₹3.75 -37.5% | 5,900 | ₹224.45 0% | 2500% |
| - | - | 5,950 | - | - |
| 34,12522.97% | ₹2.65 -27.39% | 6,000 | ₹350.75 0% | 2500% |
| 4,375337.5% | ₹2.4 -26.15% | 6,050 | - | - |
| 24,75040.42% | ₹2.5 -32.43% | 6,100 | - | - |
| 7,3750% | ₹3.4 3.03% | 6,150 | - | - |
| 4,8750% | ₹1.7 0% | 6,200 | ₹494.7 0% | 1250% |
| 2,7500% | ₹2.85 -3.38% | 6,250 | ₹614.75 0% | 00% |
| 1,125-10% | ₹1.5 -25% | 6,300 | - | - |
| 2500% | ₹2.65 0% | 6,400 | ₹804.05 4.7% | 375-50% |
| 1,6250% | ₹2 0% | 6,500 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
